After finishing at $415.44 in the prior trading day, Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) closed at $411.85, down -0.86%. In other words, the price has decreased by -$3.59 from its previous closing price. On the day, 1222035 shares were traded.
Ratios:
Our goal is to gain a better understanding of VRTX by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 9.48 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 31.88. For the most recent quarter (mrq), Quick Ratio is recorded 3.78 and its Current Ratio is at 3.99. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.04.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Wolfe Research on February 15, 2024, initiated with a Outperform rating and assigned the stock a target price of $515.
On February 06, 2024, Evercore ISI Downgraded its rating to In-line which previously was Outperform and also upped its target price recommendation from $436 to $438.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 26 ’24 when Arbuckle Stuart A sold 5,034 shares for $425.70 per share. The transaction valued at 2,142,974 led to the insider holds 49,691 shares of the business.
ALTSHULER DAVID sold 4,239 shares of VRTX for $1,804,542 on Feb 26 ’24. The EVP, Global Research and CSO now owns 25,813 shares after completing the transaction at $425.70 per share. On Feb 26 ’24, another insider, Sachdev Amit, who serves as the EVP Chief Patient & Ext Af Off of the company, sold 3,004 shares for $425.70 each. As a result, the insider received 1,278,803 and left with 55,325 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VRTX now has a Market Capitalization of 106.35B and an Enterprise Value of 95.94B. As of this moment, Vertex’s Price-to-Earnings (P/E) ratio for their current fiscal year is 29.65, and their Forward P/E ratio for the next fiscal year is 22.36. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.29. For the stock, the TTM Price-to-Sale (P/S) ratio is 10.81 while its Price-to-Book (P/B) ratio in mrq is 6.04. Its current Enterprise Value per Revenue stands at 9.72 whereas that against EBITDA is 20.83.
Stock Price History:
Over the past 52 weeks, VRTX has reached a high of $448.40, while it has fallen to a 52-week low of $283.60. The 50-Day Moving Average of the stock is 423.85, while the 200-Day Moving Average is calculated to be 371.11.
Shares Statistics:
The stock has traded on average 1.50M shares per day over the past 3-months and 1.04M shares per day over the last 10 days, according to various share statistics. A total of 257.70M shares are outstanding, with a floating share count of 257.53M. Insiders hold about 0.30% of the company’s shares, while institutions hold 92.86% stake in the company. Shares short for VRTX as of Feb 15, 2024 were 4.13M with a Short Ratio of 2.75, compared to 3.35M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 1.60% and a Short% of Float of 1.60%.
Earnings Estimates
Its stock is currently analyzed by 21 different market analysts. On average, analysts expect EPS of $4.04 for the current quarter, with a high estimate of $4.44 and a low estimate of $3.37, while EPS last year was $3.05. The consensus estimate for the next quarter is $4.12, with high estimates of $4.5 and low estimates of $3.77.
Analysts are recommending an EPS of between $18.29 and $15.15 for the fiscal current year, implying an average EPS of $16.74. EPS for the following year is $18.3, with 25 analysts recommending between $20.75 and $14.58.
Revenue Estimates
21 analysts predict $2.57B in revenue for the current quarter. It ranges from a high estimate of $2.64B to a low estimate of $2.35B. As of the current estimate, Vertex Pharmaceuticals, Inc.’s year-ago sales were $2.34B, an estimated increase of 10.10% from the year-ago figure. For the next quarter, 21 analysts are estimating revenue of $2.65B, an increase of 6.30% less than the figure of $10.10% in the same quarter last year. There is a high estimate of $2.71B for the next quarter, whereas the lowest estimate is $2.6B.
A total of 28 analysts have provided revenue estimates for VRTX’s current fiscal year. The highest revenue estimate was $10.98B, while the lowest revenue estimate was $10.6B, resulting in an average revenue estimate of $10.71B. In the same quarter a year ago, actual revenue was $9.87B, up 8.60% from the average estimate. Based on 27 analysts’ estimates, the company’s revenue will be $11.72B in the next fiscal year. The high estimate is $13.12B and the low estimate is $10.94B. The average revenue growth estimate for next year is up 9.40% from the average revenue estimate for this year.
